Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Preferred Stock Liabilities (2020 - 2021)

TScan Therapeutics (TCRX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $159.4 million as the latest value for Q2 2021.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $159.4 million in Q2 2021 year-over-year; TTM through Jun 2021 was $159.4 million, a N/A change, with the full-year FY2020 number at $59.7 million, changed N/A from a year prior.
  • Preferred Stock Liabilities was $159.4 million for Q2 2021 at TScan Therapeutics, roughly flat from $159.4 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $159.4 million in Q1 2021 to a low of $59.7 million in Q3 2020.